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A B S T R A C T
Purpose
To investigate the safety and clinical utility of the sentinel node procedure in early-stage vulvar
cancer patients.
Patients and Methods
A multicenter observational study on sentinel node detection using radioactive tracer and blue dye
was performed in patients with T1/2 ( 4 cm) squamous cell cancer of the vulva. When the
sentinel node was found to be negative at pathologic ultrastaging, inguinofemoral lymphadenec-
tomy was omitted, and the patient was observed with follow-up for 2 years at intervals of every
2 months. Stopping rules were defined for the occurrence of groin recurrences.
Results
From March 2000 until June 2006, a sentinel node procedure was performed in 623 groins of 403
assessable patients. In 259 patients with unifocal vulvar disease and a negative sentinel node
(median follow-up time, 35 months), six groin recurrences were diagnosed (2.3%; 95% CI, 0.6%
to 5%), and 3-year survival rate was 97% (95% CI, 91% to 99%). Short-term morbidity was
decreased in patients after sentinel node dissection only when compared with patients with a
positive sentinel node who underwent inguinofemoral lymphadenectomy (wound breakdown in
groin: 11.7% v 34.0%, respectively; P  .0001; and cellulitis: 4.5% v 21.3%, respectively;
P  .0001). Long-term morbidity also was less frequently observed after removal of only the
sentinel node compared with sentinel node removal and inguinofemoral lymphadenectomy
(recurrent erysipelas: 0.4% v 16.2%, respectively; P  .0001; and lymphedema of the legs: 1.9%
v 25.2%, respectively; P  .0001).
Conclusion
In early-stage vulvar cancer patients with a negative sentinel node, the groin recurrence rate is low,
survival is excellent, and treatment-related morbidity is minimal. We suggest that sentinel node
dissection, performed by a quality-controlled multidisciplinary team, should be part of the standard
treatment in selected patients with early-stage vulvar cancer.
J Clin Oncol 26:884-889. © 2008 by American Society of Clinical Oncology
INTRODUCTION
Squamous cell cancer of the vulva is a rare disease
with an annual incidenceof two to threeper 100,000
women.1-3 Current standard treatment for early-
stagedisease consists of radical excisionof the tumor
with elective inguinofemoral lymphadenectomy.
The efficacy of this treatment is good, with reported
groin recurrence rates varying between 1% and
10%.4-11 However, only 25% to 35% of patients
with early-stage disease will have lymph node
metastases,5-9 and the remaining 65% to 75% of
patients are unlikely to benefit from elective in-
guinofemoral lymphadenectomy but will be at risk
for its significant morbidity. In the short term,
wound healing in the groin is compromised by in-
fectionandbreakdownin20%to40%ofpatients. In
the long term, lymphedema of the legs with in-
creased risk for erysipelas occurs in 30% to 70% of
patients.10,12-14 Despite significant surgical morbid-
ity and a low frequency of lymph node metastases,
an elective lymphadenectomy is regarded as stan-
dard of care because unrecognized disease in the
inguinofemoral lymph nodes is nearly always fatal.
A noninvasive or minimally invasive technique
that allows the detection of inguinofemoral metas-
tases with a low false-negative rate is desirable. To
date, noninvasive imaging techniques are neither
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sensitive nor specific enough for thedetectionof (micro)metastases in
inguinofemoral lymph nodes.15,16
In a variety ofmalignancies, such as breast cancer and cutaneous
melanoma, the false-negative rate of the sentinel node procedure
seems to be low (range, 0% to 29%; average, 7.3%).17,18 In breast
cancer, not only was the nodal recurrence rate in the axilla exception-
ally low (0.1% to 0.3%), but the sentinel node procedure was also
associated with lower morbidity and improved quality of life when
compared with complete lymphadenectomy.19-23 Studies in vulvar
cancer in which sentinel node detection was followed by in-
guinofemoral lymphadenectomy suggest that the sentinel node pro-
cedure is highly accurate in identifying lymph nodemetastases with a
negativepredictive value approaching100%.24-34However, safety and
clinical utility still need tobeproven in large clinical trials.Theoptimal
design would be an equivalence randomized trial in which patients
with a negative sentinel node are randomly assigned to either obser-
vationaloneor inguinofemoral lymphadenectomy.However,because
of the low incidence of the disease and the high number of patients
needed, several collaborative groups in gynecologic cancer deemed
such a design as highly unrealistic.
The aimsof this observational studywere to investigate the safety
of omitting inguinofemoral lymphadenectomy inpatientswith a neg-
ative sentinel node and to compare short- and long-term morbidity
between sentinel node removal only and inguinofemoral lymphade-
nectomy performed in patients with a positive sentinel node. Groin
recurrences were regarded as the most serious short-term threat for
participating patients with a negative sentinel node. Therefore, for
safety reasons, stopping rules were formulated, using continuous se-
quential analysis of the occurrence of groin recurrences in the first 2
years of follow-up for each patient.
PATIENTS AND METHODS
Patients
EligiblepatientshadT1orT2, less than4cm, squamous cell cancerof the
vulva with a depth of invasion more than 1 mm and clinically nonsuspicious
inguinofemoral lymph nodes. To ensure the quality of the sentinel node
procedure in theparticipatingcenters, itwasdetermined that eachgynecologic
oncology center needed to have documented successful experience of the
sentinel node procedure with subsequent inguinofemoral lymphadenectomy
in at least 10 vulvar cancer patients (see Appendix, online only). Permission
from all local ethics committees was obtained. All patients gave written in-
formed consent. Patientswere only includedwhen registered at theUniversity
Medical Center Groningen (Groningen, the Netherlands) before the start of
treatment of the patient. Central data management was performed at the
UniversityMedical Center Groningen.
Sentinel Node Detection and Treatment Protocol
Treatment consisted of radical excision of the primary tumor in combi-
nation with sentinel node procedure. The sentinel node procedure was per-
formed with the combined technique (radioactive tracer and blue dye), as
previously described.26 After removal, sentinel nodes were sent to the pathol-
ogist as individual specimens.When the sentinel nodewasnegative, no further
treatment followed. Ifmetastatic diseasewas identified in the sentinel node, an
inguinofemoral lymphadenectomy was performed, either during the same
operation when found at frozen sectioning or during a subsequent operation
when found at routine pathologic examination or ultrastaging. When more
than one intranodal metastasis and/or extranodal growth was detected, post-
operative external-beam radiotherapy (50 Gy) to the groin/pelvis was recom-
mended (treatment protocol is detailed in Appendix).
Morbidity and Follow-Up
Data onpostoperativemorbiditywere collected in a prospective fashion.
Short-termmorbidity was defined as the occurrence of wound breakdown or
wound infection (requiring antibiotics). Patients were seen at least every 2
months for the first 2 years after treatment. Assessment included interview,
gynecologic examination, and palpation of the groins. The presence of
lymphedema (objective findings and subjective symptoms) and/or erysipelas
of the legswasdocumented.Long-termmorbidity,definedbyeither lymphed-
ema (present at two consecutive follow-up visits  1 year after primary
therapy) and/or recurrent erysipelas ( one episode of erysipelas requiring
antibiotics), was also documented.
Histopathology
The pathologic assessment of the sentinel node(s) was performed ac-
cording to a standard protocol. Briefly, the sentinel nodes were cut in the
middle for frozen section or cytologic specimen (both optional). Subse-
quently, four sectionswere cut fromeveryhalf forhematoxylinandeosin (HE)
staining (routine histopathologic examination). Ultrastaging was performed
only on sentinel nodes that were negative on routine histopathologic exami-
nation. For ultrastaging, additional pairs of sections were cut with three sec-
tions per millimeter. One section of each pair was stained with HE, and the
other section was immunostained with cytokeratin 1% AE1:AE3 antikeratin
solution (BoehringerMannheim,Mannheim,Germany). From the lymphad-
enectomy specimens, all lymph nodes were studied individually (one section
per 0.5 cm for HE staining).
Sample Size
From the literature, the groin recurrence rate after inguinofemoral
lymphadenectomy and no evidence of nodal metastases was conservatively
estimated to be 2% in early-stage vulvar cancer.4-11 An increase in groin
recurrence of 6% was considered to be the maximum acceptable increase in
lightof ananticipated significantdecrease in treatment-relatedmorbidity.Our
power calculation was based on the assumption that all groin recurrences
wouldbecomeevidentwithin thefirst 2yearsof follow-up.Toexcludea failure
rate of 8% after 2 years compared with 2%, 219 patients with 2 years of
follow-up were needed to reach a two-sided level of significance of 5% with
90%power.With final analysis 1 year after the last entry and an accrual rate of
approximately 50 patients per year, the total number of patientswould be 244.
Censoring of an estimated 30 patients for local recurrence and death not
related to vulvar cancer within 2 years would bring the needed number to 259
patients with a negative sentinel node.
Stopping Rules
To check the efficacy of our treatment protocol, stopping rules were
made regarding the rate of groin recurrences in patients with a negative
sentinel node (Fig 1). Inferiority of this failure rate to 0.02 (H0: P .02; H1:
P .08) was tested in a fully sequential design. A concomitant test of superi-
ority to 0.08 (H0: P .08; H1: P .02) was used as a test for futility. Both
tests used a constant value of , cumulating to .05 with 90% power. The
ethical committee of each participating hospital would be informed of the
activation of the stopping rule, and after the analysis of the data, the ethical
committees would be requested to judge the proposal of the investigators,
based on the results of this analysis, regarding the following: the closure of
the study; or the progression of the study with an amended protocol; or the
progression of the studywith an unchanged protocol (stopping rule design
detailed in Appendix).
Statistics
All analyses were performed using SPSS software, version 11 (SPSS Inc,
Chicago, IL). Differences in the distributions of patient characteristics were
analyzed with the 2 test. Differences between characteristics such as tumor
diameter were tested with the t test. We performed analyses of survival using
the Kaplan-Meiermethod. Differences associatedwith a P .05 were consid-
ered significant. Follow-up and survival rates were calculated from the date of
primary surgery to the date of last examination or death.
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RESULTS
Patients
FromMarch 2000 until June 2006, 457 patients from 15 centers
were registered (see Appendix). All centers had fulfilled the quality
criteria. The median number of registered patients per center was 21
(range, three to 113 patients). In 403 patients, a sentinel node proce-
dure according to the protocol was performed. The clinical character-
istics of these patients are listed in Table 1. In 127 (31.5%) of 403
patients,pathologyshowedonemetastatic sentinelnode, andthere-
fore, a total of 276 (68.5%) of 403 patients were eligible for the obser-
vational study.
Sentinel Node Characteristics
In 623 groins of 403 patients, a sentinel node procedure was
performed (183 patients only unilateral). In 163 groins (26.2%),
metastatic sentinel node(s) were found. Routine pathologic exam-
ination detected 95 (58.3%) of 163 groins with metastatic sentinel
nodes, and ultrastaging detected 68 (41.7%) of 163 groins with
metastatic sentinel nodes.
Short-Term and Long-Term Complications
For analyses of short-termmorbidity, only patients who under-
went a sentinel node procedure and inguinofemoral lymphadenec-
tomy within the same procedure were included (n  47). In the
observational study, 12patientsunderwent inguinofemoral lymphad-
enectomy in the contralateral groin. Formorbidity analyses, theywere
included in the lymphadenectomy group. Fourteen patients were
excludedbecause they received radiotherapy insteadof lymphadenec-
tomy, three patients refused, two patients died, and one patient had
recurrent disease before start of adjuvant treatment. Both short-term
and long-term morbidity were less common in patients who under-
went sentinel node removal alone compared with patients with a
metastatic sentinel node who subsequently underwent inguinofemo-
ral lymphadenectomy (Table 2). Patients who received postoperative
radiotherapy in addition to lymphadenectomy experienced recurrent
erysipelas more frequently than patients who underwent lymphade-
nectomy without postoperative radiotherapy (5.9% v 30.6%, respec-
tively; P .0001). Themedian hospital stay for patients after sentinel
node removal only was 8.4 days compared with 13.7 days for patients
who underwent an inguinofemoral lymphadenectomy immediately
after a sentinel node was found positive at frozen section (P .0001).
Stopping Rules
InOctober 2003, of 139 patientswith a negative sentinel node on
study, twopatientswithmultifocaldisease (twoseparatevulvar lesions
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Fig 1. Stopping rules for patients with unifocal disease. The gray line indicates
inferiority to a groin recurrence rate of 0.02; the yellow line indicates superiority
to 0.08. The yellow (“safe”) boundary was passed by the light blue events line
when 126 patients with unifocal vulvar cancer and a negative sentinel lymph
node had completed 2 years of follow-up without groin recurrences. Patients
were censored at time of death by other causes than vulvar cancer or local
recurrence.
Table 1. Characteristics of 403 Patients Who Underwent the Sentinel
Node Procedure According to the Protocol
Characteristic No. of Patients %
Location of primary tumor
Lateral 151 37.5
Midline 252 62.5
Disease
Unifocal 377 93.5
Multifocal 26 6.5
Treatment of vulvar tumor
Wide local excision 358 88.8
Radical vulvectomy 41 10.2
Radiotherapy† 4 1.0
A lateral tumor is defined as a tumor that has a median margin located  1
cm from the midline. A midline tumor is defined as a tumor that has a median
margin located  1 cm from the midline.
†Because of localization close to the anal sphincter.
Table 2. Short- and Long-Term Morbidity After SLN Procedure Alone
Compared With SLN With Subsequent Inguinofemoral Lymphadenectomy
Morbidity
SLN
Dissection Only
SLN
Dissection Plus
Lymphadenectomy P
Short term
Total No. of patients 264 47
Wound breakdown, groin  .0001
No. of patients 31 16
% 11.7 34.0
Cellulitis  .0001
No. of patients 12 10
% 4.5 21.3
Hospital stay, days 8.4 13.7  .0001
Long term
Total No. of patients 264 119†
Lymphedema  .0001
No. of patients 5 30
% 1.9 25.2
Recurrent erysipelas  .0001
No. of patients 1 19‡
% 0.4 16.2
Abbreviation: SLN, sentinel lymph node.
For comparison of short-term morbidity, only patients who had a complete
lymphadenectomy within the same procedure as the SLN dissection proce-
dure were included in the analysis (n  47).
†Long-term morbidity was compared between 264 patients after SLN
dissection only (276 patients in the observational study minus four patients
who had unilateral lymphadenectomy because of an SLN dissection that was
not found, and minus eight patients who had one positive node in one groin in
the observational study and had a lymphadenectomy on the contralateral side)
and 119 patients who had undergone full lymphadenectomy either in the
same session as the SLN procedures or at a second procedure (n  119).
‡Out of a total of 117 patients.
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that were injected separately) and a negative sentinel node suffered
froma groin recurrencewithin a short period of time.Despite the fact
that the stopping rules had not yet been activated, it was decided to
amend the protocol and to further exclude patients with multifocal
disease.This amendmentwas approvedby the ethics committees in all
participating centers. Figure 1 shows the performance of the stopping
rule for the observational study in unifocal patients at the time of
activation because of passing the safety border. At that time, the groin
recurrence rate forpatientswhohadcompleted2yearsof follow-up(n
 126)was 4.0% (95%CI, 1.6% to 8.0%). After reaching the number
of 259 patients with unifocal disease and a negative sentinel node, the
study was closed in June 2006.
Follow-Up in Sentinel Node–Negative Patients
Groin recurrences. The median follow-up time of the 276 pa-
tients in the observational study (17 with multifocal disease) was 35
months (range, 2 to 87 months; date of final analysis: July 1, 2007).
Four patients without recurrence were lost to follow-up and did not
complete theminimumof 24months of follow-up. Currently, 202 of
276 patients have completed at least 24months of follow-up. In eight
of 276 patients, groin recurrences were observed after a negative sen-
tinel node procedure (two with multifocal disease). The actuarial
groin recurrence rate after 2 years was 3% (95%CI, 1% to 6%) for all
patients and 2.3% (95% CI, 1.0% to 5.0%) for patients with unifocal
disease. Median time to groin recurrence was 12 months (range, 5 to
16months; Fig 2A). All patients with a groin recurrence underwent a
bilateral inguinofemoral lymphadenectomyandadjuvant (chemo)ra-
diation. Locoregional control was achieved in four of eight patients.
Six patients died of disease, whereas two are alive without evidence of
disease (50 and 6months after treatment of recurrence). Twopatients
had only one sentinel node removed, whereas the lymphoscintigram
showed two sentinel nodes. Two patients had micrometastases at
ultrastaging that were only detected at pathology review. In the re-
maining four patients, no obvious explanation for failure was found,
but two of the patients hadmultifocal disease.
Local recurrences and disease-specific and overall survival. During
follow-up, 16 (5.8%) of 276 patients died of intercurrent disease, and
10patients (3.6%)diedofvulvar cancer. In34patients (12.3%), a local
recurrence occurred (median time to recurrence, 16months; range, 2
to 67months). Treatment in these patientswas at the discretion of the
individual center.Fivepatientswith local recurrenceeventuallydiedof
distant metastases (15, 18, 22, 41, and 41 months after primary treat-
ment). Figure 2B shows the disease-specific survival curve for patients
with negative sentinel nodes. The 3-year disease-specific survival rate
for patients with unifocal vulvar disease and negative sentinel nodes
was 97.0%.
DISCUSSION
This prospective study is the largest study on surgical techniques ever
performed in vulvar cancer. The low groin recurrence rate (3% in-
cludingmultifocal disease; 2.3% in unifocal vulvar disease) and excel-
lent disease-specific survival rate of 97% at 3 years in sentinel node–
negative patients suggest that the sentinel node procedure is a safe
alternative to elective inguinofemoral lymphadenectomy for selected
vulvar cancer patients. Apart from two small, single-institution series
fromwhichnoconclusionswith respect to efficacy and safety couldbe
drawn, comparable data in vulvar cancer do not exist.32,33 The pri-
mary end point in our study was groin recurrence rate because groin
recurrences are often fatal9 and of major concern when considering a
less radical approach of the groin in vulvar cancer. Groin recurrence
rates in often small, retrospective studies vary from 0% to 5.8% for
lymphnode–negativepatients8,10,11(seeAppendix).Thegroinrecurrence
rate in sentinel node–negativepatients in the current study seems tobe at
least comparable to that reported for patients with early-stage vulvar
cancer treatedwith formal lymphadenectomyof any type.
The nodal recurrence risk may seem less favorable when com-
paredwith that seenafter the sentinelnodeprocedure in the treatment
of breast cancer (0.1% to 0.3%).35 This might be partly explained by
the fact that themajority of breast cancerpatientswill receive adjuvant
treatment after surgery,whereas vulvar cancer patientswith anegative
sentinel node do not receive any adjuvant treatment. However, from
studies where the sentinel node procedure was followed by formal
lymphadenectomy, the variation in false-negative rates (range, 0% to
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Fig 2. (A) Cumulative proportion of groin recurrences in patients with unifocal
vulvar cancer and negative sentinel node (dark blue line); 95% CIs are also given
(light blue lines). (B) Disease-specific survival curve for early-stage, unifocal vulvar
cancer patients with a negative sentinel node.
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27%; average, 6.7%)17 seems to be higher in breast cancer than the
variation found for the sentinel node procedure in vulvar cancer
(typically 0% to 2%).
The excellent performance of the sentinel node technique in
vulvar cancer is perhaps surprising given that the accuracy of the
sentinel node procedure is strongly associated with the experience of
the surgeon. In the Axillary Lymphatic Mapping Against Nodal Axil-
lary Clearance trial in breast cancer, centers were only allowed to
participate after at least 40 successful sentinel node procedures fol-
lowed by full axillary lymphadenectomy.21 Even in countries where
treatment of vulvar cancer is centralized, such figures are not realistic
because of the rarity of the disease. It may be that themore superficial
location of the inguinofemoral region compared with the axillary
region facilitates easier and thusmore accurate detection, even by less
experienced surgeons such as in our multicenter study. However, in
depth analysis of our eight patientswith false-negative results revealed
surgeon- and procedure-related factors in four of eight patients,
stressing thenecessity of strict adherence to the sentinel nodeprotocol
by the entire multidisciplinary team to prevent false-negative results.
Therefore, implementation of the sentinel node procedure in routine
treatment of early-stage vulvar cancer requires quality control at each
step of this multidisciplinary procedure, including injection of radio-
active tracer by either the surgeon or a nuclear medicine physician
familiar with vulvar anatomy, careful interpretation of lymphoscinti-
gram, a surgeon with successful experience (sentinel node procedure
followed by full lymphadenectomy) in at least 10 patients, and a
pathology department experienced in ultrastaging of the sentinel
nodes. All sentinel nodes that are negative at routineHE examination
need to be further analyzed by ultrastaging. Finally, to keep the expe-
rience at a high level, an exposure of at least five to 10 patients per year
per surgeon should be regarded as aminimumfigure. In a rare tumor
such as vulvar cancer, this will require centralization of early-stage
vulvar cancer treatment in oncology centers.
Two years after the activation of the study, a protocol amend-
ment was made when two groin recurrences occurred in 19 patients
withmultifocaldisease.Analysis revealed thatperitumoral injectionof
the tracer in multifocal disease seemed likely to not be representative
of the extent of the tumors. Fortunately, no further recurrences were
observed in the additional 19 patients with negative sentinel nodes
already registered on the study. If all patients with multifocal disease
are excluded, only six groin recurrences occurred, pointing to an even
lower groin recurrence rate (six of 259 patients; 2.3%; 95%CI, 1% to
5%). Apart from multifocal disease, we also excluded patients with
tumors greater than 4 cm fromour study. Although this figurewas arbi-
trarily chosen, representative injection of tracer around larger tumors is
less likely.Furthermore,nodal involvement increaseswith lesionsize, and
alterations in lymphatic flow that may occur with large involved nodes
could further increase the likelihoodof false-negative results.35
Themain purpose of the introduction of the sentinel node tech-
nique in early-stage vulvar cancer is reduction of treatment-related
morbidity in patients without metastatic nodes. We have shown that
sentinel node removal alone resulted in less short- and long-term
morbidity compared with inguinofemoral lymphadenectomy. The
rates of short- and long-termmorbidity after inguinofemoral lymph-
adenectomy in this study were comparable to those reported in the
literature.10,12-14 Long-termmorbidity was especially high in patients
who underwent inguinofemoral lymphadenectomy followed by ra-
diotherapy. In theongoingGroningenInternationalStudyonSentinel
Nodes inVulvarCancer-II study,patientswithametastatic sentinelnode
will receive radiotherapy insteadof inguinofemoral lymphadenectomyto
reducemorbidity caused by double-modality treatment.
In conclusion, our study demonstrates that the introduction of the
sentinel node procedure in themanagement of early-stage vulvar cancer
performed by a quality-controlled multidisciplinary team results in de-
creased morbidity without compromising groin recurrence or survival
rates. Sentinel node detection should be discussed as a safe treatment
optionwhencounselingapatientwithunifocal, early-stagevulvarcancer.
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